Budigalimab
- Generic Name
- Budigalimab
- Drug Type
- Biotech
- CAS Number
- 2098225-93-3
- Unique Ingredient Identifier
- 6VDO4TY3OO
- Background
Budigalimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Budigalimab in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
- Conditions
- Non Small Cell Lung Carcinoma
- Interventions
- First Posted Date
- 2025-01-13
- Last Posted Date
- 2025-05-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 172
- Registration Number
- NCT06772623
- Locations
- 🇺🇸
Providence - St. Jude Medical Center /ID# 271414, Fullerton, California, United States
🇺🇸FOMAT Medical Research - Clinica mi Salud by Focil Med /ID# 274450, Oxnard, California, United States
🇺🇸Mid Florida Hematology And Oncology Center /ID# 273777, Orange City, Florida, United States
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)
- Conditions
- Urothelial Carcinoma
- Interventions
- First Posted Date
- 2024-10-09
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 150
- Registration Number
- NCT06632951
- Locations
- 🇺🇸
Highlands Oncology Group - Springdale /ID# 270290, Springdale, Arkansas, United States
🇺🇸University of California San Francisco - Mission Bay /ID# 270289, San Francisco, California, United States
🇺🇸Medical Oncology Hematology Consultants /ID# 271347, Newark, Delaware, United States
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
- Conditions
- Locally Advanced Unresectable or Metastatic Gastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaEsophageal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-10-04
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 180
- Registration Number
- NCT06628310
- Locations
- 🇺🇸
City of Hope National Medical Center /ID# 268690, Duarte, California, United States
🇺🇸City of Hope Orange County Lennar Foundation Cancer Center /ID# 272630, Irvine, California, United States
🇺🇸UCLA - Santa Monica /ID# 270024, Santa Monica, California, United States
A Study to Assess the Adverse Events and How Intravenously Infused Livmoniplimab in Combination With Budigalimab Moves Through the Bodies of Adult Chinese Participants With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma (HCC)
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2025-03-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT06487559
- Locations
- 🇨🇳
Henan Cancer Hospital /ID# 262098, Zhengzhou, Henan, China
🇨🇳Beijing Youan Hospital, Capital Medical University -No differernce with previous /ID# 261928, Beijing, Beijing, China
🇨🇳Mengchao Hepatobiliary Hospital of Fujian Medical University /ID# 262443, Fuzhou, Fujian, China
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 840
- Registration Number
- NCT06236438
- Locations
- 🇺🇸
Renovatio Clinical /ID# 261999, The Woodlands, Texas, United States
🇺🇸Moores Cancer Center /ID# 267782, La Jolla, California, United States
🇺🇸Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States
A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors
- First Posted Date
- 2023-12-06
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 192
- Registration Number
- NCT06158958
- Locations
- 🇺🇸
NYU Langone - Laura and Isaac Perlmutter Cancer Center /ID# 256943, New York, New York, United States
🇺🇸City of Hope /ID# 254303, Duarte, California, United States
🇺🇸City of Hope at Orange County Lennar Foundation Cancer Center /ID# 266792, Irvine, California, United States
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 660
- Registration Number
- NCT06109272
- Locations
- 🇫🇷
Hopital Beaujon /ID# 256551, Clichy, Ile-de-France, France
🇫🇷CHU Grenoble - Hopital Michallon /ID# 256627, La Tronche, Isere, France
🇺🇸City of Hope /ID# 261468, Duarte, California, United States
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382
- Conditions
- Human Immuno-deficiency Virus (HIV) Disease
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-01-16
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 163
- Registration Number
- NCT06032546
- Locations
- 🇺🇸
University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549, Birmingham, Alabama, United States
🇺🇸Franco Felizarta, Md /Id# 256927, Bakersfield, California, United States
🇺🇸AHF Research Center /ID# 257025, Beverly Hills, California, United States
Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)
- Conditions
- Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 120
- Registration Number
- NCT05822752
- Locations
- 🇺🇸
Rocky Mountain Cancer Centers - Denver Midtwon /ID# 254163, Denver, Colorado, United States
🇮🇹IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 253247, Bologna, Emilia-Romagna, Italy
🇺🇸Arizona Oncology Associates, PC - NAHOA Prescott Valley /ID# 254313, Prescott Valley, Arizona, United States
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 350
- Registration Number
- NCT05599984
- Locations
- 🇪🇸
Hospital Santa Creu i Sant Pau /ID# 257294, Barcelona, Spain
🇪🇸Hospital Universitario Ramon y Cajal /ID# 257291, Madrid, Spain
🇪🇸Hospital Universitario Fundacion Jimenez Diaz /ID# 257295, Madrid, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.